Update shared on01 Aug 2025
Fair value Increased 17%The consensus analyst price target for Aurinia Pharmaceuticals has increased to $11.57, reflecting heightened investor optimism as evidenced by a higher future P/E ratio, despite a modest decline in net profit margin.
What's in the News
- Aurinia Pharmaceuticals raised its 2025 total revenue guidance to $260–$270 million and net product sales guidance to $250–$260 million.
- The company was removed from multiple Russell value and small-cap indices but added to the Russell 2000 Defensive and Growth-Defensive indices.
- Positive Phase 1 results announced for aritinercept (AUR200), with robust antibody reductions and favorable safety/tolerability.
- Post-hoc analysis of Phase 3 AURORA 1 study showed LUPKYNIS-based triple immunosuppressive therapy led to higher rates of reduced proteinuria and potential CV risk modification in lupus nephritis patients.
- Completed buyback of 14,560,138 shares (10.25% of shares outstanding) for $108.28 million.
Valuation Changes
Summary of Valuation Changes for Aurinia Pharmaceuticals
- The Consensus Analyst Price Target has significantly risen from $10.00 to $11.57.
- The Future P/E for Aurinia Pharmaceuticals has significantly risen from 8.59x to 10.80x.
- The Net Profit Margin for Aurinia Pharmaceuticals has fallen from 41.88% to 39.07%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.